Adalimumab, etanercept and infliximab for ankylosing spondylitis.

GUIDELINE TITLE
Adalimumab, etanercept and infliximab for ankylosing spondylitis.

BIBLIOGRAPHIC SOURCE(S)
National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept and infliximab for ankylosing spondylitis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 May. 47 p. (Technology appraisal guidance; no. 143).

GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

August 4, 2009 - Tumor Necrosis Factor (TNF) Blockers (Remicade, Enbrel, Humira, Cimzia, and Simponi): The U.S. Food and Drug Administration (FDA) notified healthcare professionals that it has completed its analysis of tumor necrosis factor (TNF) blockers and has concluded that there is an increased risk of lymphoma and other cancers associated with the use of these drugs in children and adolescents. This new safety information is now being added to the Boxed Warning for these products. FDA has also identified new safety information related to the occurrence of leukemia and new-onset psoriasis in patients treated with TNF blockers.

abrir aquí para acceder al documento NGC AHRQ completo:
Adalimumab, etanercept and infliximab for ankylosing spondylitis.

back-up:
Adalimumab, etanercept and infliximab for ankylosing spondylitis.